Call: +91 8766 590 1366   |   [email protected]

Total $0
View Cart Checkout
Total $0
View Cart Checkout

Grab 20% OFF on all Premium Reports*
product image

Global Glial Cell Line Derived Neurotrophic Factor Market Research Report 2026

Global Glial Cell Line Derived Neurotrophic Factor Market Research Report 2026

Pages: 210

Format: PDF

Date: 01-2026

Request Sample   Request Customization
Category: Healthcare & Pharma

Comprehensive Market Report: Global GDNF (Glial Cell Line-Derived Neurotrophic Factor) Targeted Therapeutics Market

Executive Summary

The global GDNF (Glial Cell Line-Derived Neurotrophic Factor) Targeted Therapeutics market represents a pioneering and high-stakes frontier in neurotherapeutics and regenerative medicine. GDNF is a potent protein that promotes the survival of key neuronal populations, making it a prime therapeutic target for a range of debilitating neurodegenerative disorders. As a clinical-stage, pipeline-driven market with significant technical and delivery challenges, it was valued at an estimated USD XX million in 2025, reflecting early-stage R&D investment. The market is poised for transformative growth upon first regulatory approvals, projected to reach USD YY billion by 2036, advancing at an exceptional Compound Annual Growth Rate (CAGR) of Z% from 2026 to 2036. This growth is contingent upon clinical trial success, the development of effective delivery platforms, and the ability to address profound unmet needs in neurology. This report provides a strategic analysis of the competitive pipeline, therapeutic modalities, and critical success factors.

1. Segments Analysis

By Therapeutic Modality & Delivery Platform:

  • Recombinant GDNF Protein Infusion (Direct Delivery): The historical approach involving direct intracerebral infusion via implanted catheters and pumps (convection-enhanced delivery). Faces challenges with distribution, surgical complexity, and immunogenicity.

  • Gene Therapy: The leading contemporary modality.

    • AAV-mediated Gene Therapy: Using adeno-associated virus (AAV) vectors to deliver the GDNF gene for sustained, localized expression in the CNS (e.g., AAV2-GDNF).

    • Lentiviral Vector Gene Therapy: Alternative viral vectors for long-term gene expression.

  • Cell Therapy (GDNF-Secreting Cells): Implantation of encapsulated cell biodelivery devices or engineered stem cells (neural progenitor cells, mesenchymal stem cells) designed to secrete GDNF locally.

  • Small Molecule GDNF Enhancers: Compounds designed to upregulate endogenous GDNF expression or mimic its signaling pathway activation. An emerging, less invasive segment.

By Target Indication (Clinical Development Focus):

  • Parkinson’s Disease (PD): The primary and most advanced indication. Aims to protect and potentially restore dopaminergic neurons in the substantia nigra. Represents the largest potential market.

  • Amyotrophic Lateral Sclerosis (ALS): Targets motor neuron survival. High unmet need but complex pathophysiology.

  • Neuropathic Pain & Chronic Pain Conditions: GDNF's role in sensory neuron survival makes it a target for intractable pain (e.g., diabetic neuropathy, chemotherapy-induced peripheral neuropathy).

  • Hearing Loss & Auditory Neuropathy: Preclinical and early-stage focus on spiral ganglion neuron protection.

  • Other Neurodegenerative & Retinal Diseases: Includes Huntington’s disease, Alzheimer’s disease, and retinal degeneration (via neuroprotection of photoreceptors).

By Stage of Development:

  • Clinical-Stage Pipeline (Phases I-III): High-risk, high-value segment where most current value resides. Success in Phase II proof-of-concept is the critical inflection point.

  • Preclinical & Discovery: Long-term pipeline feeding the clinical segment.

2. Key Players

The market is dominated by specialized biotechnology companies, often in partnership with larger pharma, and academic spin-outs.

Leading Companies & Collaborators:

  • Neurocrine Biosciences, Inc. (In partnership with Voyager Therapeutics on VY-AADC01 and GDNF-targeted programs)

  • Brain Neurotherapy Bio, Inc. (Developing GDNF gene therapy for Parkinson's)

  • Asklepios BioPharmaceutical, Inc. (AskBio) (AAV gene therapy platform, GDNF programs)

  • UniQure N.V. (AAV gene therapy platform, CNS focus)

  • Sangamo Therapeutics, Inc. (Gene regulation and editing platforms with CNS applications)

  • Ceregene Inc. (historical leader, assets now with others)

  • Astellas Pharma Inc. (Through acquisitions and partnerships in gene therapy)

  • Novartis AG (Interest in neuroscience and gene therapy)

  • MeiraGTx Holdings plc (Gene therapy platform with AAV capabilities)

  • Treeway BV (Focus on ALS therapies)

  • Handl Therapeutics (GDNF gene therapy for Parkinson's)

  • Lysogene (AAV gene therapy for CNS diseases)

  • Genzyme (a Sanofi company) (Historical expertise, ongoing interest in rare neurology)

3. Regional Analysis

  • North America: The unequivocal leader in R&D investment, clinical trial activity, and anticipated first commercialization. The U.S. FDA’s experience with advanced CNS therapies and its regulatory pathways (RMAT, Fast Track) will guide initial approvals. Largest concentration of specialist trial sites.

  • Europe: A major collaborative hub for neuroscience research and clinical development. The EMA will be a critical second regulatory authority. Strong academic centers in the UK, France, and Sweden drive early-phase trials.

  • Asia-Pacific: A growing region for clinical trial recruitment and future market access. Japan’s PMDA has an advanced regulatory framework for regenerative medicine, making it a potential early-launch market. Australia and South Korea have strong research ecosystems.

  • Latin America, Middle East & Africa: Limited to participation in global multi-regional clinical trials at leading centers. Commercial access will lag significantly and will be restricted to high-income, private-pay patients in major cities.

4. Porter’s Five Forces Analysis

  • Competitive Rivalry (Moderate but Specialized): Competition is currently moderate as programs target different diseases/delivery methods. Rivalry will intensify within specific indications (e.g., Parkinson's disease) upon late-stage clinical readouts. It is a "winner-take-most" dynamic per indication.

  • Bargaining Power of Suppliers (High for Specialized Inputs): Suppliers of critical, specialized components hold high power. This includes viral vector CDMOs (with limited global capacity), specialized neurosurgical device manufacturers for delivery systems, and providers of GMP-grade plasmids/cell lines.

  • Bargaining Power of Buyers (Very High): Ultimate buyers are government payers and insurers. Given the expected multi-million-dollar price tags for one-time gene therapies, payers will exert extreme pressure, demanding unprecedented outcomes-based contracts and long-term efficacy/durability data.

  • Threat of New Entrants (Moderate): Scientific and technical barriers are immense (BBB penetration, targeted delivery, immunogenicity). However, new entrants with novel platform technologies (e.g., next-gen vectors, non-viral delivery) or alternative neurotrophic factors (e.g., CDNF, Neurturin) can emerge.

  • Threat of Substitutes (Moderate to High): Includes other neuroprotective strategies (e.g., alpha-synuclein-targeting therapies for PD), symptomatic drug therapies, deep brain stimulation (DBS), and supportive care. GDNF therapies aim to be disease-modifying, a value proposition that, if proven, would reduce the threat from purely symptomatic substitutes.

5. SWOT Analysis

  • Strengths: Strong biological rationale for neuronal protection/restoration; potential to be first disease-modifying therapy for several indications; benefits from orphan drug and regenerative medicine designations (accelerated pathways, market exclusivity).

  • Weaknesses: Immense historical challenges with delivery to the CNS and achieving adequate biodistribution; very high cost of development and manufacturing; complex, invasive administration often requiring neurosurgery; risk of immunogenic responses.

  • Opportunities: Successful demonstration of disease modification in a major indication (e.g., PD) would unlock blockbuster potential and validate the entire neurotrophic factor approach. Expansion into other neurological and sensory disorders.

  • Threats: Clinical trial failures due to delivery inefficacy or safety issues; long-term durability and safety unknowns for gene/cell therapies; catastrophic reimbursement challenges and payer refusal; ethical and surgical risks associated with invasive delivery.

6. Trend Analysis, Drivers & Challenges

Key Trends:

  • Dominance of AAV Gene Therapy Platform: The shift from protein infusion to one-time AAV gene therapy for sustained, localized GDNF production is the defining trend.

  • Focus on Targeted Delivery & Biodistribution: Intensive R&D on novel capsids (e.g., AAV9, PHP.eB, AAV.CPP.16) and delivery routes (intraparenchymal, intrathecal, intra-CSF) to improve brain penetration and targeting.

  • Biomarker-Driven Development: Use of advanced imaging (PET, MRI) and fluid biomarkers to select patients, measure target engagement, and objectively assess therapeutic effect in trials.

  • Combination Therapy Approaches: Exploration of GDNF therapy in combination with other agents (e.g., to enhance neuronal growth competence or modulate the neuronal environment).

Primary Drivers:

  1. Profound Unmet Medical Need: Lack of disease-modifying therapies for Parkinson's, ALS, and other neurodegenerative diseases creates immense pressure for innovation.

  2. Advancements in Gene Therapy & Delivery Technology: Progress in vector design, manufacturing, and neurosurgical techniques enabling renewed clinical attempts.

  3. Strong Patient Advocacy & Regulatory Incentives: Well-organized patient groups and regulatory agencies providing accelerated pathways for serious conditions.

  4. High Value of Potential Success: The commercial reward for a successful disease-modifying CNS therapy is among the highest in biopharma, driving investment.

Critical Challenges:

  1. The Blood-Brain Barrier (BBB) & Delivery: The paramount scientific and technical hurdle. Ensuring sufficient GDNF reaches the correct neurons at therapeutic levels without widespread distribution.

  2. Clinical Trial Design & Endpoints: Defining and achieving clinically meaningful endpoints in slowly progressive diseases within a feasible trial timeline.

  3. Manufacturing Complexity & Cost: Scalable, consistent GMP manufacturing of viral vectors or cell products is extremely costly and complex.

  4. Reimbursement & Market Access: Justifying potentially ultra-high one-time costs to healthcare systems, requiring revolutionary pricing and payment models.

7. Value Chain Analysis

  1. Basic Research & Discovery: Academic and institutional research identifying GDNF's role and validating targets.

  2. Platform & Vector Development: Engineering of viral vectors, cell lines, or delivery devices – the core proprietary technology.

  3. Preclinical & Translational Research: Extensive animal model testing to establish proof-of-concept, dosing, and safety.

  4. Clinical Development (Phases I-III): The most value-critical and capital-intensive phase, involving complex neurosurgery, imaging, and neurology endpoints.

  5. Regulatory Strategy & Submission: Navigating unprecedented regulatory discussions with FDA/EMA for a novel class of invasive neuro-restorative therapies.

  6. Commercial Manufacturing & Supply Chain: Building or contracting ultra-specialized, low-volume, high-cost GMP facilities for final drug product.

  7. Specialized Administration Network: Establishing a limited network of expert neurosurgical centers qualified to administer the therapy.

  8. Market Access, Pricing & Outcomes Management: The ultimate commercial gatekeeper. Requires novel agreements linking payment to long-term outcomes.
    Value is overwhelmingly concentrated in successful late-stage clinical data (Phase II/III) and proprietary delivery platform technology. The chain is R&D-heavy with commercialization funneled through a few specialist centers.

8. Quick Recommendations for Stakeholders

  • For Biotechnology Innovators (Neurocrine/Voyager, AskBio, etc.): Prioritize solving the delivery challenge above all else—this is the key differentiator. Design trials with objective biomarker endpoints alongside clinical measures. Forge early and deep partnerships with payers and health technology assessment (HTA) bodies to co-create viable reimbursement models. Secure specialized manufacturing capacity early.

  • For Large Pharmaceutical Companies: Act as strategic partners or acquirers of promising platforms post-proof-of-concept. Provide capital, regulatory expertise, and commercial infrastructure. Invest in building the specialized medical affairs and surgical support networks required for launch.

  • For Investors: This is a high-risk, high-reward, binary investment thesis. Focus on companies with novel delivery technology and strong clinical leadership. The most significant value inflection is a positive Phase II proof-of-concept readout. Diversify across modalities and indications within the neurotrophic factor space.

  • For Regulatory Agencies (FDA, EMA): Develop adaptive and flexible frameworks for evaluating these complex therapies. Collaborate on defining acceptable surrogate endpoints and novel trial designs. Prepare for the post-marketing surveillance challenges of lifelong follow-up for one-time therapies.

  • For Healthcare Providers & Payers: Begin planning now for the systemic impact of a successful therapy. This includes identifying qualified treatment centers, developing patient selection criteria, and designing innovative outcomes-based financing models (e.g., annuities, warranty models) to manage cost and risk over a patient's lifetime.

Report Basis: History Years: 2020-2024; Base Year: 2025; Forecast Period: 2026-2036.
Note: All market values (XX, YY) and CAGR (Z%) are illustrative placeholders. This is a speculative analysis of a pre-commercial, pipeline-dependent market. Customized data, including probability-adjusted revenue forecasting, deep-dive pipeline analysis, and technology platform benchmarking, is available per client specifications.

 

Table of Contents

Global Glial Cell Line Derived Neurotrophic Factor Sales Market Report 2018
1 Glial Cell Line Derived Neurotrophic Factor Market Overview
    1.1 Product Overview and Scope of Glial Cell Line Derived Neurotrophic Factor
    1.2 Classification of Glial Cell Line Derived Neurotrophic Factor by Product Category
        1.2.1 Global Glial Cell Line Derived Neurotrophic Factor Market Size (Sales) Comparison by Type
        1.2.2 Global Glial Cell Line Derived Neurotrophic Factor Market Size (Sales) Market Share by Type (Product Category) in
        1.2.3 GSK-812
        1.2.4 LAUR-301
        1.2.5 TW-002
        1.2.6 AMT-090
        1.2.7 Others
    1.3 Global Glial Cell Line Derived Neurotrophic Factor Market by Application/End Users
        1.3.1 Global Glial Cell Line Derived Neurotrophic Factor Sales (Volume) and Market Share Comparison by Application
        1.3.1 Amyotrophic Lateral Sclerosis
        1.3.2 Brain Ischemia
        1.3.3 Parkinson's Disease
        1.3.4 Retinal Degeneration
        1.3.5 Others
    1.4 Global Glial Cell Line Derived Neurotrophic Factor Market by Region
        1.4.1 Global Glial Cell Line Derived Neurotrophic Factor Market Size (Value) Comparison by Region
        1.4.2 United States Glial Cell Line Derived Neurotrophic Factor Status and Prospect
        1.4.3 Europe Glial Cell Line Derived Neurotrophic Factor Status and Prospect
        1.4.4 China Glial Cell Line Derived Neurotrophic Factor Status and Prospect
        1.4.5 Japan Glial Cell Line Derived Neurotrophic Factor Status and Prospect
        1.4.6 Southeast Asia Glial Cell Line Derived Neurotrophic Factor Status and Prospect
        1.4.7 India Glial Cell Line Derived Neurotrophic Factor Status and Prospect
    1.5 Global Market Size (Value and Volume) of Glial Cell Line Derived Neurotrophic Factor
        1.5.1 Global Glial Cell Line Derived Neurotrophic Factor Sales and Growth Rate
        1.5.2 Global Glial Cell Line Derived Neurotrophic Factor Revenue and Growth Rate

2 Global Glial Cell Line Derived Neurotrophic Factor Competition by Players/Suppliers, Type and Application
     2.1 Global Glial Cell Line Derived Neurotrophic Factor Market Competition by Players/Suppliers
        2.1.1 Global Glial Cell Line Derived Neurotrophic Factor Sales and Market Share of Key Players/Suppliers ()
        2.1.2 Global Glial Cell Line Derived Neurotrophic Factor Revenue and Share by Players/Suppliers ()
    2.2 Global Glial Cell Line Derived Neurotrophic Factor (Volume and Value) by Type
        2.2.1 Global Glial Cell Line Derived Neurotrophic Factor Sales and Market Share by Type ()
        2.2.2 Global Glial Cell Line Derived Neurotrophic Factor Revenue and Market Share by Type ()
    2.3 Global Glial Cell Line Derived Neurotrophic Factor (Volume and Value) by Region
        2.3.1 Global Glial Cell Line Derived Neurotrophic Factor Sales and Market Share by Region ()
        2.3.2 Global Glial Cell Line Derived Neurotrophic Factor Revenue and Market Share by Region ()
    2.4 Global Glial Cell Line Derived Neurotrophic Factor (Volume) by Application

3 United States Glial Cell Line Derived Neurotrophic Factor (Volume, Value and Sales Price)
    3.1 United States Glial Cell Line Derived Neurotrophic Factor Sales and Value ()
        3.1.1 United States Glial Cell Line Derived Neurotrophic Factor Sales and Growth Rate ()
        3.1.2 United States Glial Cell Line Derived Neurotrophic Factor Revenue and Growth Rate ()
        3.1.3 United States Glial Cell Line Derived Neurotrophic Factor Sales Price Trend ()
    3.2 United States Glial Cell Line Derived Neurotrophic Factor Sales Volume and Market Share by Players ()
    3.3 United States Glial Cell Line Derived Neurotrophic Factor Sales Volume and Market Share by Type ()
    3.4 United States Glial Cell Line Derived Neurotrophic Factor Sales Volume and Market Share by Application ()

4 Europe Glial Cell Line Derived Neurotrophic Factor (Volume, Value and Sales Price)
    4.1 Europe Glial Cell Line Derived Neurotrophic Factor Sales and Value ()
        4.1.1 Europe Glial Cell Line Derived Neurotrophic Factor Sales and Growth Rate ()
        4.1.2 Europe Glial Cell Line Derived Neurotrophic Factor Revenue and Growth Rate ()
        4.1.3 Europe Glial Cell Line Derived Neurotrophic Factor Sales Price Trend ()
    4.2 Europe Glial Cell Line Derived Neurotrophic Factor Sales Volume and Market Share by Players ()
    4.3 Europe Glial Cell Line Derived Neurotrophic Factor Sales Volume and Market Share by Type ()
    4.4 Europe Glial Cell Line Derived Neurotrophic Factor Sales Volume and Market Share by Application ()

5 China Glial Cell Line Derived Neurotrophic Factor (Volume, Value and Sales Price)
    5.1 China Glial Cell Line Derived Neurotrophic Factor Sales and Value ()
        5.1.1 China Glial Cell Line Derived Neurotrophic Factor Sales and Growth Rate ()
        5.1.2 China Glial Cell Line Derived Neurotrophic Factor Revenue and Growth Rate ()
        5.1.3 China Glial Cell Line Derived Neurotrophic Factor Sales Price Trend ()
    5.2 China Glial Cell Line Derived Neurotrophic Factor Sales Volume and Market Share by Players ()
    5.3 China Glial Cell Line Derived Neurotrophic Factor Sales Volume and Market Share by Type ()
    5.4 China Glial Cell Line Derived Neurotrophic Factor Sales Volume and Market Share by Application ()

6 Japan Glial Cell Line Derived Neurotrophic Factor (Volume, Value and Sales Price)
    6.1 Japan Glial Cell Line Derived Neurotrophic Factor Sales and Value ()
        6.1.1 Japan Glial Cell Line Derived Neurotrophic Factor Sales and Growth Rate ()
        6.1.2 Japan Glial Cell Line Derived Neurotrophic Factor Revenue and Growth Rate ()
        6.1.3 Japan Glial Cell Line Derived Neurotrophic Factor Sales Price Trend ()
    6.2 Japan Glial Cell Line Derived Neurotrophic Factor Sales Volume and Market Share by Players ()
    6.3 Japan Glial Cell Line Derived Neurotrophic Factor Sales Volume and Market Share by Type ()
    6.4 Japan Glial Cell Line Derived Neurotrophic Factor Sales Volume and Market Share by Application ()

7 Southeast Asia Glial Cell Line Derived Neurotrophic Factor (Volume, Value and Sales Price)
    7.1 Southeast Asia Glial Cell Line Derived Neurotrophic Factor Sales and Value ()
        7.1.1 Southeast Asia Glial Cell Line Derived Neurotrophic Factor Sales and Growth Rate ()
        7.1.2 Southeast Asia Glial Cell Line Derived Neurotrophic Factor Revenue and Growth Rate ()
        7.1.3 Southeast Asia Glial Cell Line Derived Neurotrophic Factor Sales Price Trend ()
    7.2 Southeast Asia Glial Cell Line Derived Neurotrophic Factor Sales Volume and Market Share by Players ()
    7.3 Southeast Asia Glial Cell Line Derived Neurotrophic Factor Sales Volume and Market Share by Type ()
    7.4 Southeast Asia Glial Cell Line Derived Neurotrophic Factor Sales Volume and Market Share by Application ()

8 India Glial Cell Line Derived Neurotrophic Factor (Volume, Value and Sales Price)
    8.1 India Glial Cell Line Derived Neurotrophic Factor Sales and Value ()
        8.1.1 India Glial Cell Line Derived Neurotrophic Factor Sales and Growth Rate ()
        8.1.2 India Glial Cell Line Derived Neurotrophic Factor Revenue and Growth Rate ()
        8.1.3 India Glial Cell Line Derived Neurotrophic Factor Sales Price Trend ()
    8.2 India Glial Cell Line Derived Neurotrophic Factor Sales Volume and Market Share by Players ()
    8.3 India Glial Cell Line Derived Neurotrophic Factor Sales Volume and Market Share by Type ()
    8.4 India Glial Cell Line Derived Neurotrophic Factor Sales Volume and Market Share by Application ()

9 Global Glial Cell Line Derived Neurotrophic Factor Players/Suppliers Profiles and Sales Data
    9.1 GlaxoSmithKline Plc
        9.1.1 Company Basic Information, Manufacturing Base and Competitors
        9.1.2 Glial Cell Line Derived Neurotrophic Factor Product Category, Application and Specification
            9.1.2.1 Product A
            9.1.2.2 Product B
        9.1.3 GlaxoSmithKline Plc Glial Cell Line Derived Neurotrophic Factor Sales, Revenue, Price and Gross Margin ()
        9.1.4 Main Business/Business Overview
    9.2 Treeway BV
        9.2.1 Company Basic Information, Manufacturing Base and Competitors
        9.2.2 Glial Cell Line Derived Neurotrophic Factor Product Category, Application and Specification
            9.2.2.1 Product A
            9.2.2.2 Product B
        9.2.3 Treeway BV Glial Cell Line Derived Neurotrophic Factor Sales, Revenue, Price and Gross Margin ()
        9.2.4 Main Business/Business Overview
    9.3 UniQure NV
        9.3.1 Company Basic Information, Manufacturing Base and Competitors
        9.3.2 Glial Cell Line Derived Neurotrophic Factor Product Category, Application and Specification
            9.3.2.1 Product A
            9.3.2.2 Product B
        9.3.3 UniQure NV Glial Cell Line Derived Neurotrophic Factor Sales, Revenue, Price and Gross Margin ()
        9.3.4 Main Business/Business Overview
    ...

10 Glial Cell Line Derived Neurotrophic Factor Maufacturing Cost Analysis
    10.1 Glial Cell Line Derived Neurotrophic Factor Key Raw Materials Analysis
        10.1.1 Key Raw Materials
        10.1.2 Price Trend of Key Raw Materials
        10.1.3 Key Suppliers of Raw Materials
        10.1.4 Market Concentration Rate of Raw Materials
    10.2 Proportion of Manufacturing Cost Structure
        10.2.1 Raw Materials
        10.2.2 Labor Cost
        10.2.3 Manufacturing Process Analysis of Glial Cell Line Derived Neurotrophic Factor
    10.3 Manufacturing Process Analysis of Glial Cell Line Derived Neurotrophic Factor

11 Industrial Chain, Sourcing Strategy and Downstream Buyers
    11.1 Glial Cell Line Derived Neurotrophic Factor Industrial Chain Analysis
    11.2 Upstream Raw Materials Sourcing
    11.3 Raw Materials Sources of Glial Cell Line Derived Neurotrophic Factor Major Manufacturers in
    11.4 Downstream Buyers

12 Marketing Strategy Analysis, Distributors/Traders
    12.1 Marketing Channel
        12.1.1 Direct Marketing
        12.1.2 Indirect Marketing
        12.1.3 Marketing Channel Development Trend
    12.2 Market Positioning
        12.2.1 Pricing Strategy
        12.2.2 Brand Strategy
        12.2.3 Target Client
    12.3 Distributors/Traders List

13 Market Effect Factors Analysis
    13.1 Technology Progress/Risk
        13.1.1 Substitutes Threat
        13.1.2 Technology Progress in Related Industry
    13.2 Consumer Needs/Customer Preference Change
    13.3 Economic/Political Environmental Change

14 Global Glial Cell Line Derived Neurotrophic Factor Market Forecast (2018-2025)
    14.1 Global Glial Cell Line Derived Neurotrophic Factor Sales Volume, Revenue and Price Forecast (2018-2025)
       14.1.1 Global Glial Cell Line Derived Neurotrophic Factor Sales Volume and Growth Rate Forecast (2018-2025)
       14.1.2 Global Glial Cell Line Derived Neurotrophic Factor Revenue and Growth Rate Forecast (2018-2025)
       14.1.3 Global Glial Cell Line Derived Neurotrophic Factor Price and Trend Forecast (2018-2025)
    14.2 Global Glial Cell Line Derived Neurotrophic Factor Sales Volume, Revenue and Growth Rate Forecast by Region (2018-2025)
       14.2.1 Global Glial Cell Line Derived Neurotrophic Factor Sales Volume and Growth Rate Forecast by Regions (2018-2025)
       14.2.2 Global Glial Cell Line Derived Neurotrophic Factor Revenue and Growth Rate Forecast by Regions (2018-2025)
       14.2.3 United States Glial Cell Line Derived Neurotrophic Factor Sales Volume, Revenue and Growth Rate Forecast (2018-2025)
       14.2.4 Europe Glial Cell Line Derived Neurotrophic Factor Sales Volume, Revenue and Growth Rate Forecast (2018-2025)
       14.2.5 China Glial Cell Line Derived Neurotrophic Factor Sales Volume, Revenue and Growth Rate Forecast (2018-2025)
       14.2.6 Japan Glial Cell Line Derived Neurotrophic Factor Sales Volume, Revenue and Growth Rate Forecast (2018-2025)
       14.2.7 Southeast Asia Glial Cell Line Derived Neurotrophic Factor Sales Volume, Revenue and Growth Rate Forecast (2018-2025)
       14.2.8 India Glial Cell Line Derived Neurotrophic Factor Sales Volume, Revenue and Growth Rate Forecast (2018-2025)
    14.3 Global Glial Cell Line Derived Neurotrophic Factor Sales Volume, Revenue and Price Forecast by Type (2018-2025)
       14.3.1 Global Glial Cell Line Derived Neurotrophic Factor Sales Forecast by Type (2018-2025)
       14.3.2 Global Glial Cell Line Derived Neurotrophic Factor Revenue Forecast by Type (2018-2025)
       14.3.3 Global Glial Cell Line Derived Neurotrophic Factor Price Forecast by Type (2018-2025)
    14.4 Global Glial Cell Line Derived Neurotrophic Factor Sales Volume Forecast by Application (2018-2025)

15 Research Findings and Conclusion

16 Appendix
    16.1 Methodology/Research Approach
        16.1.1 Research Programs/Design
        16.1.2 Market Size Estimation
        16.1.3 Market Breakdown and Data Triangulation
    16.2 Data Source
        16.2.1 Secondary Sources
        16.2.2 Primary Sources
    16.3 Disclaimer
List of Tables and Figures

    Figure Product Picture of Glial Cell Line Derived Neurotrophic Factor
    Figure Global Glial Cell Line Derived Neurotrophic Factor Sales Volume Comparison (K Pcs) by Type
    Figure Global Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Type (Product Category) in
    Figure GSK-812 Product Picture
    Figure LAUR-301 Product Picture
    Figure TW-002 Product Picture
    Figure AMT-090 Product Picture
    Figure Others Product Picture
    Figure Global Glial Cell Line Derived Neurotrophic Factor Sales Comparison (K Pcs) by Application
    Figure Global Sales Market Share of Glial Cell Line Derived Neurotrophic Factor by Application in
    Figure Amyotrophic Lateral Sclerosis Examples
    Table Key Downstream Customer in Amyotrophic Lateral Sclerosis
    Figure Brain Ischemia Examples
    Table Key Downstream Customer in Brain Ischemia
    Figure Parkinson's Disease Examples
    Table Key Downstream Customer in Parkinson's Disease
    Figure Retinal Degeneration Examples
    Table Key Downstream Customer in Retinal Degeneration
    Figure Others Examples
    Table Key Downstream Customer in Others
    Figure Global Glial Cell Line Derived Neurotrophic Factor Market Size (Million USD) by Regions
    Figure United States Glial Cell Line Derived Neurotrophic Factor Revenue (Million USD) and Growth Rate
    Figure Europe Glial Cell Line Derived Neurotrophic Factor Revenue (Million USD) and Growth Rate
    Figure China Glial Cell Line Derived Neurotrophic Factor Revenue (Million USD) and Growth Rate
    Figure Japan Glial Cell Line Derived Neurotrophic Factor Revenue (Million USD) and Growth Rate
    Figure Southeast Asia Glial Cell Line Derived Neurotrophic Factor Revenue (Million USD) and Growth Rate
    Figure India Glial Cell Line Derived Neurotrophic Factor Revenue (Million USD) and Growth Rate
    Figure Global Glial Cell Line Derived Neurotrophic Factor Sales Volume (K Pcs) and Growth Rate
    Figure Global Glial Cell Line Derived Neurotrophic Factor Revenue (Million USD) and Growth Rate
    Figure Global Market Major Players Glial Cell Line Derived Neurotrophic Factor Sales Volume (K Pcs) ()
    Table Global Glial Cell Line Derived Neurotrophic Factor Sales (K Pcs) of Key Players/Suppliers ()
    Table Global Glial Cell Line Derived Neurotrophic Factor Sales Share by Players/Suppliers ()
    Figure  Glial Cell Line Derived Neurotrophic Factor Sales Share by Players/Suppliers
    Figure  Glial Cell Line Derived Neurotrophic Factor Sales Share by Players/Suppliers
    Figure Global Glial Cell Line Derived Neurotrophic Factor Revenue (Million USD) by Players/Suppliers ()
    Table Global Glial Cell Line Derived Neurotrophic Factor Revenue (Million USD) by Players/Suppliers ()
    Table Global Glial Cell Line Derived Neurotrophic Factor Revenue Share by Players/Suppliers ()
    Table  Global Glial Cell Line Derived Neurotrophic Factor Revenue Share by Players
    Table  Global Glial Cell Line Derived Neurotrophic Factor Revenue Share by Players
    Table Global Glial Cell Line Derived Neurotrophic Factor Sales (K Pcs) and Market Share by Type ()
    Table Global Glial Cell Line Derived Neurotrophic Factor Sales Share (K Pcs) by Type ()
    Figure Sales Market Share of Glial Cell Line Derived Neurotrophic Factor by Type ()
    Figure Global Glial Cell Line Derived Neurotrophic Factor Sales Growth Rate by Type ()
    Table Global Glial Cell Line Derived Neurotrophic Factor Revenue (Million USD) and Market Share by Type ()
    Table Global Glial Cell Line Derived Neurotrophic Factor Revenue Share by Type ()
    Figure Revenue Market Share of Glial Cell Line Derived Neurotrophic Factor by Type ()
    Figure Global Glial Cell Line Derived Neurotrophic Factor Revenue Growth Rate by Type ()
    Table Global Glial Cell Line Derived Neurotrophic Factor Sales Volume (K Pcs) and Market Share by Region ()
    Table Global Glial Cell Line Derived Neurotrophic Factor Sales Share by Region ()
    Figure Sales Market Share of Glial Cell Line Derived Neurotrophic Factor by Region ()
    Figure Global Glial Cell Line Derived Neurotrophic Factor Sales Growth Rate by Region in
    Table Global Glial Cell Line Derived Neurotrophic Factor Revenue (Million USD) and Market Share by Region ()
    Table Global Glial Cell Line Derived Neurotrophic Factor Revenue Share (%) by Region ()
    Figure Revenue Market Share of Glial Cell Line Derived Neurotrophic Factor by Region ()
    Figure Global Glial Cell Line Derived Neurotrophic Factor Revenue Growth Rate by Region in
    Table Global Glial Cell Line Derived Neurotrophic Factor Revenue (Million USD) and Market Share by Region ()
    Table Global Glial Cell Line Derived Neurotrophic Factor Revenue Share (%) by Region ()
    Figure Revenue Market Share of Glial Cell Line Derived Neurotrophic Factor by Region ()
    Figure Global Glial Cell Line Derived Neurotrophic Factor Revenue Market Share by Region in
    Table Global Glial Cell Line Derived Neurotrophic Factor Sales Volume (K Pcs) and Market Share by Application ()
    Table Global Glial Cell Line Derived Neurotrophic Factor Sales Share (%) by Application ()
    Figure Sales Market Share of Glial Cell Line Derived Neurotrophic Factor by Application ()
    Figure Global Glial Cell Line Derived Neurotrophic Factor Sales Market Share by Application ()
    Figure United States Glial Cell Line Derived Neurotrophic Factor Sales (K Pcs) and Growth Rate ()
    Figure United States Glial Cell Line Derived Neurotrophic Factor Revenue (Million USD) and Growth Rate ()
    Figure United States Glial Cell Line Derived Neurotrophic Factor Sales Price (USD/Pcs) Trend ()
    Table United States Glial Cell Line Derived Neurotrophic Factor Sales Volume (K Pcs) by Players ()
    Table United States Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Players ()
    Figure United States Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Players in
    Table United States Glial Cell Line Derived Neurotrophic Factor Sales Volume (K Pcs) by Type ()
    Table United States Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Type ()
    Figure United States Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Type in
    Table United States Glial Cell Line Derived Neurotrophic Factor Sales Volume (K Pcs) by Application ()
    Table United States Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Application ()
    Figure United States Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Application in
    Figure Europe Glial Cell Line Derived Neurotrophic Factor Sales (K Pcs) and Growth Rate ()
    Figure Europe Glial Cell Line Derived Neurotrophic Factor Revenue (Million USD) and Growth Rate ()
    Figure Europe Glial Cell Line Derived Neurotrophic Factor Sales Price (USD/Pcs) Trend ()
    Table Europe Glial Cell Line Derived Neurotrophic Factor Sales Volume (K Pcs) by Players ()
    Table Europe Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Players ()
    Figure Europe Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Players in
    Table Europe Glial Cell Line Derived Neurotrophic Factor Sales Volume (K Pcs) by Type ()
    Table Europe Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Type ()
    Figure Europe Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Type in
    Table Europe Glial Cell Line Derived Neurotrophic Factor Sales Volume (K Pcs) by Application ()
    Table Europe Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Application ()
    Figure Europe Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Application in
    Figure China Glial Cell Line Derived Neurotrophic Factor Sales (K Pcs) and Growth Rate ()
    Figure China Glial Cell Line Derived Neurotrophic Factor Revenue (Million USD) and Growth Rate ()
    Figure China Glial Cell Line Derived Neurotrophic Factor Sales Price (USD/Pcs) Trend ()
    Table China Glial Cell Line Derived Neurotrophic Factor Sales Volume (K Pcs) by Players ()
    Table China Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Players ()
    Figure China Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Players in
    Table China Glial Cell Line Derived Neurotrophic Factor Sales Volume (K Pcs) by Type ()
    Table China Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Type ()
    Figure China Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Type in
    Table China Glial Cell Line Derived Neurotrophic Factor Sales Volume (K Pcs) by Application ()
    Table China Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Application ()
    Figure China Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Application in
    Figure Japan Glial Cell Line Derived Neurotrophic Factor Sales (K Pcs) and Growth Rate ()
    Figure Japan Glial Cell Line Derived Neurotrophic Factor Revenue (Million USD) and Growth Rate ()
    Figure Japan Glial Cell Line Derived Neurotrophic Factor Sales Price (USD/Pcs) Trend ()
    Table Japan Glial Cell Line Derived Neurotrophic Factor Sales Volume (K Pcs) by Players ()
    Table Japan Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Players ()
    Figure Japan Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Players in
    Table Japan Glial Cell Line Derived Neurotrophic Factor Sales Volume (K Pcs) by Type ()
    Table Japan Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Type ()
    Figure Japan Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Type in
    Table Japan Glial Cell Line Derived Neurotrophic Factor Sales Volume (K Pcs) by Application ()
    Table Japan Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Application ()
    Figure Japan Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Application in
    Figure Southeast Asia Glial Cell Line Derived Neurotrophic Factor Sales (K Pcs) and Growth Rate ()
    Figure Southeast Asia Glial Cell Line Derived Neurotrophic Factor Revenue (Million USD) and Growth Rate ()
    Figure Southeast Asia Glial Cell Line Derived Neurotrophic Factor Sales Price (USD/Pcs) Trend ()
    Table Southeast Asia Glial Cell Line Derived Neurotrophic Factor Sales Volume (K Pcs) by Players ()
    Table Southeast Asia Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Players ()
    Figure Southeast Asia Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Players in
    Table Southeast Asia Glial Cell Line Derived Neurotrophic Factor Sales Volume (K Pcs) by Type ()
    Table Southeast Asia Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Type ()
    Figure Southeast Asia Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Type in
    Table Southeast Asia Glial Cell Line Derived Neurotrophic Factor Sales Volume (K Pcs) by Application ()
    Table Southeast Asia Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Application ()
    Figure Southeast Asia Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Application in
    Figure India Glial Cell Line Derived Neurotrophic Factor Sales (K Pcs) and Growth Rate ()
    Figure India Glial Cell Line Derived Neurotrophic Factor Revenue (Million USD) and Growth Rate ()
    Figure India Glial Cell Line Derived Neurotrophic Factor Sales Price (USD/Pcs) Trend ()
    Table India Glial Cell Line Derived Neurotrophic Factor Sales Volume (K Pcs) by Players ()
    Table India Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Players ()
    Figure India Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Players in
    Table India Glial Cell Line Derived Neurotrophic Factor Sales Volume (K Pcs) by Type ()
    Table India Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Type ()
    Figure India Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Type in
    Table India Glial Cell Line Derived Neurotrophic Factor Sales Volume (K Pcs) by Application ()
    Table India Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Application ()
    Figure India Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share by Application in
    Table GlaxoSmithKline Plc Basic Information List
    Table GlaxoSmithKline Plc Glial Cell Line Derived Neurotrophic Factor Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin ()
    Figure GlaxoSmithKline Plc Glial Cell Line Derived Neurotrophic Factor Sales Growth Rate ()
    Figure GlaxoSmithKline Plc Glial Cell Line Derived Neurotrophic Factor Sales Global Market Share ()
    Figure GlaxoSmithKline Plc Glial Cell Line Derived Neurotrophic Factor Revenue Global Market Share ()
    Table Treeway BV Basic Information List
    Table Treeway BV Glial Cell Line Derived Neurotrophic Factor Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin ()
    Figure Treeway BV Glial Cell Line Derived Neurotrophic Factor Sales Growth Rate ()
    Figure Treeway BV Glial Cell Line Derived Neurotrophic Factor Sales Global Market Share ()
    Figure Treeway BV Glial Cell Line Derived Neurotrophic Factor Revenue Global Market Share ()
    Table UniQure NV Basic Information List
    Table UniQure NV Glial Cell Line Derived Neurotrophic Factor Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin ()
    Figure UniQure NV Glial Cell Line Derived Neurotrophic Factor Sales Growth Rate ()
    Figure UniQure NV Glial Cell Line Derived Neurotrophic Factor Sales Global Market Share (
    Figure UniQure NV Glial Cell Line Derived Neurotrophic Factor Revenue Global Market Share ()
    Table Production Base and Market Concentration Rate of Raw Material
    Figure Price Trend of Key Raw Materials
    Table Key Suppliers of Raw Materials
    Figure Manufacturing Cost Structure of Glial Cell Line Derived Neurotrophic Factor
    Figure Manufacturing Process Analysis of Glial Cell Line Derived Neurotrophic Factor
    Figure Glial Cell Line Derived Neurotrophic Factor Industrial Chain Analysis
    Table Raw Materials Sources of Glial Cell Line Derived Neurotrophic Factor Major Players in
    Table Major Buyers of Glial Cell Line Derived Neurotrophic Factor
    Table Distributors/Traders List
    Figure Global Glial Cell Line Derived Neurotrophic Factor Sales Volume (K Pcs) and Growth Rate Forecast (2018-2025)
    Figure Global Glial Cell Line Derived Neurotrophic Factor Revenue (Million USD) and Growth Rate Forecast (2018-2025)
    Figure Global Glial Cell Line Derived Neurotrophic Factor Price (USD/Pcs) and Trend Forecast (2018-2025)
    Table Global Glial Cell Line Derived Neurotrophic Factor Sales Volume (K Pcs) Forecast by Regions (2018-2025)
    Figure Global Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share Forecast by Regions (2018-2025)
    Figure Global Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share Forecast by Regions in 2025
    Table Global Glial Cell Line Derived Neurotrophic Factor Revenue (Million USD) Forecast by Regions (2018-2025)
    Figure Global Glial Cell Line Derived Neurotrophic Factor Revenue Market Share Forecast by Regions (2018-2025)
    Figure Global Glial Cell Line Derived Neurotrophic Factor Revenue Market Share Forecast by Regions in 2025
    Figure United States Glial Cell Line Derived Neurotrophic Factor Sales Volume (K Pcs) and Growth Rate Forecast (2018-2025)
    Figure United States Glial Cell Line Derived Neurotrophic Factor Revenue (Million USD) and Growth Rate Forecast (2018-2025)
    Figure Europe Glial Cell Line Derived Neurotrophic Factor Sales Volume (K Pcs) and Growth Rate Forecast (2018-2025)
    Figure Europe Glial Cell Line Derived Neurotrophic Factor Revenue and Growth Rate Forecast (2018-2025)
    Figure China Glial Cell Line Derived Neurotrophic Factor Sales Volume (K Pcs) and Growth Rate Forecast (2018-2025)
    Figure China Glial Cell Line Derived Neurotrophic Factor Revenue (Million USD) and Growth Rate Forecast (2018-2025)
    Figure Japan Glial Cell Line Derived Neurotrophic Factor Sales Volume (K Pcs) and Growth Rate Forecast (2018-2025)
    Figure Japan Glial Cell Line Derived Neurotrophic Factor Revenue (Million USD) and Growth Rate Forecast (2018-2025)
    Figure Southeast Asia Glial Cell Line Derived Neurotrophic Factor Sales Volume (K Pcs) and Growth Rate Forecast (2018-2025)
    Figure Southeast Asia Glial Cell Line Derived Neurotrophic Factor Revenue (Million USD) and Growth Rate Forecast (2018-2025)
    Figure India Glial Cell Line Derived Neurotrophic Factor Sales Volume (K Pcs) and Growth Rate Forecast (2018-2025)
    Figure India Glial Cell Line Derived Neurotrophic Factor Revenue (Million USD) and Growth Rate Forecast (2018-2025)
    Table Global Glial Cell Line Derived Neurotrophic Factor Sales (K Pcs) Forecast by Type (2018-2025)
    Figure Global Glial Cell Line Derived Neurotrophic Factor Sales Volume Market Share Forecast by Type (2018-2025)
    Table Global Glial Cell Line Derived Neurotrophic Factor Revenue (Million USD) Forecast by Type (2018-2025)
    Figure Global Glial Cell Li

1. Segments Analysis

By Therapeutic Modality & Delivery Platform:

  • Recombinant GDNF Protein Infusion (Direct Delivery): The historical approach involving direct intracerebral infusion via implanted catheters and pumps (convection-enhanced delivery). Faces challenges with distribution, surgical complexity, and immunogenicity.

  • Gene Therapy: The leading contemporary modality.

    • AAV-mediated Gene Therapy: Using adeno-associated virus (AAV) vectors to deliver the GDNF gene for sustained, localized expression in the CNS (e.g., AAV2-GDNF).

    • Lentiviral Vector Gene Therapy: Alternative viral vectors for long-term gene expression.

  • Cell Therapy (GDNF-Secreting Cells): Implantation of encapsulated cell biodelivery devices or engineered stem cells (neural progenitor cells, mesenchymal stem cells) designed to secrete GDNF locally.

  • Small Molecule GDNF Enhancers: Compounds designed to upregulate endogenous GDNF expression or mimic its signaling pathway activation. An emerging, less invasive segment.

By Target Indication (Clinical Development Focus):

  • Parkinson’s Disease (PD): The primary and most advanced indication. Aims to protect and potentially restore dopaminergic neurons in the substantia nigra. Represents the largest potential market.

  • Amyotrophic Lateral Sclerosis (ALS): Targets motor neuron survival. High unmet need but complex pathophysiology.

  • Neuropathic Pain & Chronic Pain Conditions: GDNF's role in sensory neuron survival makes it a target for intractable pain (e.g., diabetic neuropathy, chemotherapy-induced peripheral neuropathy).

  • Hearing Loss & Auditory Neuropathy: Preclinical and early-stage focus on spiral ganglion neuron protection.

  • Other Neurodegenerative & Retinal Diseases: Includes Huntington’s disease, Alzheimer’s disease, and retinal degeneration (via neuroprotection of photoreceptors).

By Stage of Development:

  • Clinical-Stage Pipeline (Phases I-III): High-risk, high-value segment where most current value resides. Success in Phase II proof-of-concept is the critical inflection point.

  • Preclinical & Discovery: Long-term pipeline feeding the clinical segment.

2. Key Players

The market is dominated by specialized biotechnology companies, often in partnership with larger pharma, and academic spin-outs.

Leading Companies & Collaborators:

  • Neurocrine Biosciences, Inc. (In partnership with Voyager Therapeutics on VY-AADC01 and GDNF-targeted programs)

  • Brain Neurotherapy Bio, Inc. (Developing GDNF gene therapy for Parkinson's)

  • Asklepios BioPharmaceutical, Inc. (AskBio) (AAV gene therapy platform, GDNF programs)

  • UniQure N.V. (AAV gene therapy platform, CNS focus)

  • Sangamo Therapeutics, Inc. (Gene regulation and editing platforms with CNS applications)

  • Ceregene Inc. (historical leader, assets now with others)

  • Astellas Pharma Inc. (Through acquisitions and partnerships in gene therapy)

  • Novartis AG (Interest in neuroscience and gene therapy)

  • MeiraGTx Holdings plc (Gene therapy platform with AAV capabilities)

  • Treeway BV (Focus on ALS therapies)

  • Handl Therapeutics (GDNF gene therapy for Parkinson's)

  • Lysogene (AAV gene therapy for CNS diseases)

  • Genzyme (a Sanofi company) (Historical expertise, ongoing interest in rare neurology)

FAQ's

Yes, we are providing all research support to get resolve all queries and concerns regarding the report. For all our clients.
Yes, we are providing complete customization in every report to fulfill your business needs.
Yes, we are providing regional and countries level analysis in the report, please mention the countries you are looking.
Yes, we are providing a discount for individuals and startups.
We offer access to more than one million market research reports. If the specific topic you need is not listed on our website, simply email us your requirements at [email protected]. Our research team will review your request and provide a customized report or the most relevant available study. We

Similar Reports

Product image
View
Healthcare & Pharma

Dull Skin Treatment Market

$3100
Product image
View
Healthcare & Pharma

Global Microbiology Culture Market Report

$3100
Product image
View
Healthcare & Pharma

Global Cosmetic Laser Market Report

$3100
Product image
View
Healthcare & Pharma

Global Glycomics Market Report

$3100